Updates from the ongoing placebo-controlled Phase 2/3 FALCON-HD trial – HDBuzz

Huntington’s disease research news.

In plain language. Written by scientists.
For the global HD community.

HDBuzz Trial Tracker

Expected submission for regulatory approval of AMT-130 in the UK

uniQure

Expected: Q3 2026

Expected submission of BLA for regulatory approval of AMT-130 in the US

uniQure

Expected: Q3 2026

Sites for Phase 3 trial for votoplam, INVEST-HD, now open. Updates on recruitment and first dosing imminent.

Novartis/PTC Therapeutics

Expected: Spring 2026

Show 9 more Show less

REGEN4HD, Phase 1 stem cell implantation study commences

University of California, Irvine

Expected: Not disclosed

Phase 3 for SOM3355 to commence

SOM Biotech

Expected: Q4 2026

Progress update for NCT06585449 – A Study to Evaluate ALN-HTT02

Alnylam Pharmaceuticals

Expected: 2026

Update on Planned Phase 2/3 Study for WVE-003

Wave Life Sciences

Expected: Not disclosed

Update on Phase 1/2a Clinical Data of VO659

Vico Therapeutics

Expected: Not disclosed

First participant in Phase 1/2 gene therapy trial dosed

Roche

Expected: Not disclosed

Updates on data leading to closing of GENERATION-HD2 trial

Roche

Expected: Not disclosed

Updates on data leading to closing of POINT-HD trial

Roche

Expected: Not disclosed

Updates from the ongoing placebo-controlled Phase 2/3 FALCON-HD trial

Skyhawk Therapeutics

Expected: Not disclosed